MX2011009822A - Derivados de tienopirimidinadiona como moduladores del trpa1. - Google Patents
Derivados de tienopirimidinadiona como moduladores del trpa1.Info
- Publication number
- MX2011009822A MX2011009822A MX2011009822A MX2011009822A MX2011009822A MX 2011009822 A MX2011009822 A MX 2011009822A MX 2011009822 A MX2011009822 A MX 2011009822A MX 2011009822 A MX2011009822 A MX 2011009822A MX 2011009822 A MX2011009822 A MX 2011009822A
- Authority
- MX
- Mexico
- Prior art keywords
- acetamide
- dioxo
- tetrahydrothieno
- dimethyl
- thiazol
- Prior art date
Links
- QAFVXBQPQCSSLI-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)NC2=C1SC=C2 QAFVXBQPQCSSLI-UHFFFAOYSA-N 0.000 title abstract 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 10
- 201000010099 disease Diseases 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 97
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- -1 cyano, hydroxyl Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 3
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 150000005347 biaryls Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000003349 osteoarthritic effect Effects 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 150000000177 1,2,3-triazoles Chemical class 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- YMCJSZIUTZMYST-UHFFFAOYSA-N N-[4-[3-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(=CS1)C1=CC(OC(F)(F)F)=CC=C1 YMCJSZIUTZMYST-UHFFFAOYSA-N 0.000 claims 1
- KCAZYBRGKJKRLO-UHFFFAOYSA-N N-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(=CS1)C1=CC(=C(F)C=C1)C(F)(F)F KCAZYBRGKJKRLO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| IN2213MU2009 | 2009-09-23 | ||
| US25199409P | 2009-10-15 | 2009-10-15 | |
| IN2906MU2009 | 2009-12-16 | ||
| US29447010P | 2010-01-12 | 2010-01-12 | |
| PCT/IB2010/000930 WO2010109334A2 (en) | 2009-03-23 | 2010-03-23 | Thienopyrimidinedione derivatives as trpa1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009822A true MX2011009822A (es) | 2012-01-25 |
Family
ID=42780205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009822A MX2011009822A (es) | 2009-03-23 | 2010-03-23 | Derivados de tienopirimidinadiona como moduladores del trpa1. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20120178766A1 (enExample) |
| EP (3) | EP2411395B1 (enExample) |
| JP (2) | JP2012521406A (enExample) |
| KR (2) | KR20110128898A (enExample) |
| CN (3) | CN102361874A (enExample) |
| AP (1) | AP2948A (enExample) |
| AU (2) | AU2010227225A1 (enExample) |
| BR (2) | BRPI1013705A2 (enExample) |
| CA (2) | CA2756535A1 (enExample) |
| DK (3) | DK2411395T3 (enExample) |
| EA (2) | EA201190138A1 (enExample) |
| ES (3) | ES2424341T3 (enExample) |
| HU (1) | HUE024538T2 (enExample) |
| IL (2) | IL215177A (enExample) |
| MX (1) | MX2011009822A (enExample) |
| PE (2) | PE20120834A1 (enExample) |
| PL (3) | PL2411395T3 (enExample) |
| PT (3) | PT2411395E (enExample) |
| SG (4) | SG184767A1 (enExample) |
| SI (3) | SI2411395T1 (enExample) |
| WO (2) | WO2010109329A1 (enExample) |
| ZA (2) | ZA201107650B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551085T3 (es) | 2009-03-23 | 2015-11-16 | Glenmark Pharmaceuticals S.A. | Proceso para preparar derivados de pirimidina-diona condensados, útiles como moduladores de TRPA1 |
| CN102361874A (zh) | 2009-03-23 | 2012-02-22 | 格兰马克药品股份有限公司 | 作为trpa1调节剂的呋喃并嘧啶二酮衍生物 |
| MX336549B (es) | 2010-12-20 | 2016-01-22 | Glenmark Pharmaceuticals Sa | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| BR112013032025A2 (pt) * | 2011-06-13 | 2016-12-20 | Glenmark Pharmaceutical S A | antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação |
| CA2837429A1 (en) * | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| CA2841417A1 (en) * | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| EP2787991A1 (en) | 2011-12-05 | 2014-10-15 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| BR112014029155A2 (pt) * | 2012-06-08 | 2017-06-27 | Glenmark Pharmaceuticals Sa | amidas de compostos de 2-amino-4-ariltiazol e respectivos sais e processos de preparação |
| WO2014053694A1 (en) | 2012-10-01 | 2014-04-10 | Orion Corporation | N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists |
| MX2015016024A (es) * | 2013-06-20 | 2016-04-04 | Glenmark Pharmaceuticals Sa | Formulacion en nanoparticulas que comprende un antagonista para trpa1. |
| JP2016537322A (ja) * | 2013-10-15 | 2016-12-01 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１アンタゴニスト及び鎮痛剤を含む医薬組成物 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| EP3180345B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders |
| JP6695323B2 (ja) * | 2014-08-11 | 2020-05-20 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| US10329265B2 (en) | 2014-08-22 | 2019-06-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| CN109310683A (zh) * | 2016-04-07 | 2019-02-05 | 杜克大学 | 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂 |
| CN110461838B (zh) * | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
| CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
| WO2021074198A1 (en) | 2019-10-15 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Novel tetrazoles |
| MX2023004008A (es) * | 2020-10-14 | 2023-04-26 | Boehringer Ingelheim Int | Derivados de tetrazol como inhibidores de trpa1. |
| HUE070004T2 (hu) * | 2020-10-14 | 2025-04-28 | Boehringer Ingelheim Int | Tetrazol-származékok, mint TRPA1 inhibitorok |
| CN116940575A (zh) * | 2021-02-23 | 2023-10-24 | 深圳市康哲药业有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CA3210965A1 (en) | 2021-04-14 | 2022-10-20 | Boehringer Ingelheim International Gmbh | 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| ES2211161T3 (es) * | 1998-08-28 | 2004-07-01 | Astrazeneca Ab | Tieno(2,3-d)pirimidindionas novedosas, procedimiento para su preparacion y uso de las mismas en terapia. |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| CA2504320A1 (en) * | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| US6890923B2 (en) * | 2002-12-16 | 2005-05-10 | Astrazeneca Ab | Compounds |
| AU2003290066A1 (en) | 2002-12-18 | 2004-07-09 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| EP1657238A4 (en) | 2003-08-22 | 2008-12-03 | Takeda Pharmaceutical | CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE |
| JP2007522214A (ja) * | 2004-02-11 | 2007-08-09 | スミスクライン・ビーチャム・コーポレイション | Ｐｔｈアゴニスト |
| WO2005089206A2 (en) | 2004-03-13 | 2005-09-29 | Irm Llc | Modulators of ion channel trpa1 |
| US20090062258A1 (en) | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| JP2009503107A (ja) * | 2005-08-04 | 2009-01-29 | アポジー・バイオテクノロジー・コーポレイション | スフィンゴシンキナーゼ阻害剤およびそれらの使用方法 |
| CA2627260A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of trpv1 related disorders |
| WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
| US20070105920A1 (en) * | 2005-11-08 | 2007-05-10 | Akzo Nobel N.V. | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives |
| TW201900217A (zh) * | 2005-12-22 | 2019-01-01 | 美商海卓勒生物科學公司 | 用於調節ｔｒｐａ１功能之化合物 |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| CL2008000252A1 (es) * | 2007-01-29 | 2008-03-14 | Xenon Pharmaceuticals Inc | Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir |
| SI3184527T1 (sl) * | 2007-06-22 | 2020-03-31 | Eli Lilly And Company | Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala |
| CN101711413B (zh) * | 2007-06-25 | 2013-09-04 | 桑迪士克科技股份有限公司 | 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置 |
| WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
| CN102361874A (zh) | 2009-03-23 | 2012-02-22 | 格兰马克药品股份有限公司 | 作为trpa1调节剂的呋喃并嘧啶二酮衍生物 |
| SG184766A1 (en) | 2009-03-23 | 2012-10-30 | Glenmark Pharmaceuticals Sa | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
| AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| CA2776028C (en) | 2009-10-15 | 2015-12-01 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| IN2012DN01269A (enExample) | 2010-07-13 | 2015-05-15 | Novartis Ag |
-
2010
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/en not_active Not-in-force
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/en not_active Ceased
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Withdrawn
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 CA CA2756535A patent/CA2756535A1/en not_active Abandoned
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh not_active Expired - Fee Related
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/en not_active Ceased
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 CA CA2756536A patent/CA2756536C/en active Active
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko not_active Expired - Fee Related
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja not_active Expired - Fee Related
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 US US12/936,451 patent/US8507503B2/en not_active Expired - Fee Related
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/en active Active
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/en active Active
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en not_active Ceased
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
-
2011
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
-
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
-
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009822A (es) | Derivados de tienopirimidinadiona como moduladores del trpa1. | |
| MX2011009821A (es) | Derivados de isotiazolo pirimidinadiona como moduladores del trpa1. | |
| JP7337883B2 (ja) | 乳酸脱水素酵素の小分子阻害剤及びその使用方法 | |
| JP4972690B2 (ja) | 脂質レベルの上昇に関連する疾病の処置に適するヘテロ環式化合物 | |
| US12071433B2 (en) | HMOX1 inducers | |
| AU2010204118B2 (en) | Sulfonamide derivatives | |
| CN103342701B (zh) | 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法 | |
| KR101584826B1 (ko) | 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제 | |
| CA2729557A1 (en) | Chemical compounds 251 | |
| MX2011009824A (es) | Derivados de pirimidina-diona fusionados como moduladores del trpa1. | |
| SK20182000A3 (sk) | Činidlo regulujúce funkciu receptora súvisiaceho s retinoidmi | |
| NZ529043A (en) | Large conductance calcium-activated K channel opener | |
| MX2014015350A (es) | Compuestos de triazolona como inhibidores de mpegs-1. | |
| JP2012521405A5 (enExample) | ||
| RU2005105696A (ru) | Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы | |
| CZ20021604A3 (cs) | Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití | |
| WO2007143597A2 (en) | Organic compounds | |
| DK163990B (da) | Oxindol-3-carboxamid-derivater og farmaceutiske praeparater indeholdende disse | |
| JP2024516429A (ja) | メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用 | |
| CA2985400C (en) | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2c antagonists | |
| EP4638444A1 (en) | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | |
| AU2013200845B2 (en) | Heterocyclic inhibitors of stearoyl-CoA desaturase | |
| KR20240047432A (ko) | 융합된 고리 헤테로아릴 화합물 및 이의 용도 | |
| EA035585B1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
| NZ613592A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation |